Komori
Techno Medica (6678) · InitiativeRestated

Preparation for Applying the New Accounting Standard on Revenue Recognition

First written in FY2018. 11 of 13 entries say "Restated". Latest entry: FY2026-H1.

13entries
8years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2018 – FY2021RestatedFY2022-Q2 – FY2026-H12018: 120182019: 120192020: 020202021: 320212022: 320222023: 320232024: 120242025: 12025
Same theme, other companies
Assessment of the Impact of Applying the Accounting Standard for Revenue RecognitionA theme 83 companies write about · 1 as a headwind · 0 as a tailwind

58 other companies' latest entry also says "Restated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 83 companies compared. The sentences above are computed from all 83.
Full recordFilings, disclosures and news, newest first
  1. FY2026-H1RestatedAnnual report

    「For sales of blood collection tube preparation equipment and systems and specimen testing equipment, products are generally delivered, and revenue is recognized when the completion of operation has been confirmed, at which point control of the products is deemed to have transferred to the customer. For domestic sales of consumables and other products, revenue is recognized when the products are shipped by the Company. Transactions under maintenance contracts are recognized as revenue over the contract period.」

    Following adoption of the Revenue Recognition Accounting Standard, the Company has continued to recognize revenue for equipment and systems upon delivery and confirmation of completed operation, for consumables upon domestic shipment, and for maintenance contracts over the contract period.
  2. FY2024RestatedAnnual report

    「For sales of blood collection tube preparation equipment and systems and specimen testing equipment, products are generally delivered, and revenue is recognized when the completion of operation has been confirmed, at which point control of the products is deemed to have transferred to the customer. For domestic sales of consumables and other products, revenue is recognized when the products are shipped by the Company. Transactions under maintenance contracts are recognized as revenue over the contract period.」

    Following adoption of the Revenue Recognition Accounting Standard, the Company has continued to recognize revenue for equipment and systems upon delivery and confirmation of completed operation, for consumables upon domestic shipment, and for maintenance contracts over the contract period.
  3. FY2024-Q2RestatedAnnual report

    「For sales of blood collection tube preparation equipment and systems and specimen testing equipment, products are generally delivered, and revenue is recognized when the completion of operation has been confirmed, at which point control of the products is deemed to have transferred to the customer. For domestic sales of consumables and other products, revenue is recognized when the products are shipped by the Company. Transactions under maintenance contracts are recognized as revenue over the contract period.」

    Following adoption of the Revenue Recognition Accounting Standard, the Company has continued to recognize revenue for equipment and systems upon delivery and confirmation of completed operation, for consumables upon domestic shipment, and for maintenance contracts over the contract period.
  4. FY2024-Q1RestatedAnnual report

    「For sales of blood collection tube preparation equipment and systems and specimen testing equipment, products are generally delivered, and revenue is recognized when the completion of operation has been confirmed, at which point control of the products is deemed to have transferred to the customer.」

    Following adoption of the Revenue Recognition Accounting Standard, the Company has continued to recognize revenue for equipment and systems upon delivery and confirmation of completed operation, for consumables upon domestic shipment, and for maintenance contracts over the contract period.
  5. FY2023-Q3RestatedAnnual report

    「For sales of blood collection tube preparation equipment and systems and specimen testing equipment, products are generally delivered, and revenue is recognized when the completion of operation has been confirmed, at which point control of the products is deemed to have transferred to the customer.」

    Following adoption of the Revenue Recognition Accounting Standard, the Company has continued to recognize revenue for equipment and systems upon delivery and confirmation of completed operation.
  6. FY2023-Q2RestatedAnnual report

    「For sales of blood collection tube preparation equipment and systems and specimen testing equipment, products are generally delivered, and revenue is recognized when the completion of operation has been confirmed, at which point control of the products is deemed to have transferred to the customer.」

    Following adoption of the Revenue Recognition Accounting Standard, the Company has continued to recognize revenue for equipment and systems upon delivery and confirmation of completed operation.
  7. FY2023-Q1RestatedAnnual report

    「For sales of blood collection tube preparation equipment and systems and specimen testing equipment, products are generally delivered, and revenue is recognized when the completion of operation has been confirmed, at which point control of the products is deemed to have transferred to the customer.」

    Following adoption of the Revenue Recognition Accounting Standard, the Company has continued to recognize revenue for equipment and systems upon delivery and confirmation of completed operation, for consumables upon domestic shipment, and for maintenance contracts over the contract period.
  8. FY2022RestatedAnnual report

    「The Accounting Standard for Revenue Recognition (ASBJ Statement No. 29, 31 March 2020; hereinafter, the “Revenue Recognition Accounting Standard”) and other standards have been adopted from the beginning of the current fiscal year. Revenue is recognized at the amount expected to be received in exchange for the promised goods or services when control of those goods or services is transferred to the customer.」

    The Revenue Recognition Accounting Standard continues to be applied from the beginning of the current fiscal year, with no impact from its adoption on profit or loss for the current fiscal year or beginning retained earnings carried forward.
  9. FY2022-Q2RestatedAnnual report

    「The Accounting Standard for Revenue Recognition (ASBJ Statement No. 29, 31 March 2020) and other standards have been adopted from the beginning of the first quarter of the current fiscal year. Accordingly, the key management indicators and other information for the cumulative second-quarter period and the second quarter of the current fiscal year reflect application of these accounting standards and related standards.」

    The Revenue Recognition Accounting Standard adopted from the beginning of the first quarter has continued to be applied to the cumulative second-quarter period.
  10. FY2022-Q1AchievedAnnual report

    「The Accounting Standard for Revenue Recognition (ASBJ Statement No. 29, 31 March 2020; hereinafter, the “Revenue Recognition Accounting Standard”) and other standards have been adopted from the beginning of the first quarter of the current fiscal year. Revenue is recognized at the amount expected to be received in exchange for the promised goods or services when control of those goods or services is transferred to the customer. As a result, there was no impact on profit or loss for the cumulative first-quarter period or on the beginning balance of retained earnings.」

    The new accounting standard for revenue recognition was adopted from the beginning of the fiscal year on 1 April 2021, changing the method of revenue recognition. The Company stated that there was no impact on profit or loss or on beginning retained earnings, moving from the previous preparation stage to implementation.
  11. FY2021RestatedAnnual report

    「The standards are scheduled to be applied from the beginning of the fiscal year ending March 2022. The amount of the impact was still being assessed when these financial statements were prepared.」

    The Company has reconfirmed its plan to adopt the new accounting standard for revenue recognition from the beginning of the fiscal year ending March 2022 and that its impact remains under evaluation.
  12. FY2019RestatedAnnual report

    「The standards are scheduled to be applied from the beginning of the fiscal year ending March 2022. The amount of the impact was still being assessed when these financial statements were prepared.」

    The Company has reconfirmed that it plans to adopt the new accounting standard for revenue recognition from the beginning of the fiscal year ending March 2022 and is evaluating its impact.
  13. FY2018First statedAnnual report

    「(2) Scheduled date of adoption The standard is scheduled to be adopted from the beginning of the fiscal year ending March 2022. (3) Impact of adopting the accounting standard and related standards The amount of the impact is under evaluation as of the preparation of these financial statements.」

    The Company disclosed for the first time that it planned to adopt the new accounting standard for revenue recognition from the beginning of the fiscal year ending March 2022 and was evaluating its impact on the financial statements.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for Techno Medica yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Preparation for Applying the New Accounting Standard on Revenue Recognition | Techno Medica Co.,Ltd. (6678) | Komori